Related references
Note: Only part of the references are listed.PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
Paola Fuso et al.
CANCERS (2022)
Current and Future Management of HER2-Positive Metastatic Breast Cancer
Olga Martinez-Saez et al.
JCO ONCOLOGY PRACTICE (2021)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Carmine De Angelis et al.
CLINICAL CANCER RESEARCH (2021)
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Miguel A. Ortega et al.
JOURNAL OF ONCOLOGY (2020)
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Anna R. Michmerhuizen et al.
NPJ BREAST CANCER (2020)
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Yumi Fujimoto et al.
SCIENTIFIC REPORTS (2020)
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway
Yulong Lan et al.
CANCER BIOLOGY & MEDICINE (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells
Micaela Montanari et al.
MOLECULAR CANCER RESEARCH (2019)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
J. Veeraraghavan et al.
ANNALS OF ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
AKR1C enzymes sustain therapy resistance in paediatric T-ALL
Roberta Bortolozzi et al.
BRITISH JOURNAL OF CANCER (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F. Rimawi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl et al.
EUROPEAN JOURNAL OF CANCER (2017)
Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
Licai He et al.
SCIENTIFIC REPORTS (2017)
Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy
Chen-Ming Zeng et al.
FRONTIERS IN PHARMACOLOGY (2017)
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
Jamunarani Veeraraghavan et al.
BREAST (2017)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xiaowei Xu et al.
CLINICAL CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini et al.
BREAST CANCER RESEARCH (2017)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells
Ryuji Matsumoto et al.
SCIENTIFIC REPORTS (2016)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells
Akitomi Shirato et al.
ONCOLOGY LETTERS (2014)
Growth Rate Analysis and Efficient Experimental Design for Tumor Xenograft Studies
Gregory Hather et al.
CANCER INFORMATICS (2014)
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+breast cancer cells
Brent N. Rexer et al.
BREAST CANCER RESEARCH (2014)
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
Ariella B. Hanker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
Tamara Utermark et al.
GENES & DEVELOPMENT (2012)
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Gene ontology analysis for RNA-seq: accounting for selection bias
Matthew D. Young et al.
GENOME BIOLOGY (2010)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis
Shidong Jia et al.
NATURE (2008)
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells:: optimization of a coculture model for personalized therapy approaches
Bianca Maria Veneziani et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Share Paper
